CAR T-Cell Therapies for Multiple Myeloma

home / case-based-digest / car-t-cell-therapies-for-multiple-myeloma

As part of its Community Case Forum series, key opinion leaders and participants discuss the use of CAR T-cell therapy for the treatment of patients with multiple myeloma.

Image of multiple myeloma cells

Personalizing Neurotoxicity Monitoring After CAR T-Cell Therapy

Bridget Hoyt
August 20th 2025

Neurotoxicities can be monitored long term with personalized questions, according to Mary Steinbach, DNP, APRN.

Graphic of clinicians inspecting a large diagram of a bone with an oversized magnifying glass

What Are the Barriers to CAR T-Cell Therapy Access in Multiple Myeloma?

Bridget Hoyt
August 15th 2025

Treatment access can still affect patients in urban communities, said Mary Steinbach, DNP, APRN.

Photo of a man with a beard in front of a blue background

CAR T-Cell Therapy May Be Moving Up in Myeloma Treatment Sequencing

Nick Barkemeyer, PA-C, MMS
July 3rd 2025

CAR T-cell therapy is starting to enter treatment conversations sooner with patients with multiple myeloma, according to Nick Barkemeyer, PA-C, MMS.

nurse talking to a woman with a walker, educating her on CAR T-cell therapy side effects

Caregivers, Clinicians Must Be Familiar With CRS Risk After CAR T-Cell Therapy

Brielle Benyon
November 13th 2024

At a recent Community Case Forum, an expert discussed the risk of cytokine release syndrome after patients undergo CAR T-cell therapy.

Advancing Multiple Myeloma Treatment With CAR T-Cell Therapy

Advancing Multiple Myeloma Treatment With CAR T-Cell Therapy

Darlene Dobkowski, MA
July 10th 2024

Daniel Verina, DNP, ACNP-BC, discussed how CAR T-cell therapy is changing the treatment landscape for patients with multiple myeloma.